Genmab — Maj 2024
-
back to the Q1 call on GEN1046; Q: your data so far on LiverTox seems to be quite manageable. But just wondering what are your thoughts on the long-term safety profile on that side, any potential for accumulated LiverTox from a patient who you use it for longer? Have you seen any accumulated sort of LiverTox data?
-
A: On LiverTox you’re absolutely correct, and we have now a substantial amount of experience with the asset also in combination with PD-1 and also a decent follow-up. It seems manageable, in our hands. Patients can get reexposed after a recovery period and broadly speaking, tolerate to reexposure really well. And we have absolutely no evidence with the accumulation of liver toxicity with a, as I said, a substantial amount of patients across many trials with a relatively long follow-up
-
Genmab faller efter data för acasunlimab (Finwire) https://www.placera.se/placera/telegram/2024/05/24/genmab-genmab-faller-efter-data-for-acasunlimab.html
-
Jeg ved ikke hvem du var/er enig med Solsen…..der var da ikke nogen der var uenige da den steg. Nej, banditterne styrer løbet, og når de nu har været i stand til at handle den ned, lykkes det også at handle den på et konstant niveau……det er ikke en aktie i fri handel…..dette burde der graves dybere i….
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind